The PAS submission is a positive regulatory milestone that could expand KHINDIVI's addressable market to the largest under-5 pediatric segment. Monitor FDA review progress over the coming months; a potential approval in H1 2027 is a key catalyst. Recent insider selling ($2.1M in 30 days) warrants caution, but the overall bullish analyst consensus (89% buy) supports the long-term thesis.
Price Chart
Executive Summary
Eton Pharmaceuticals submitted a Prior Approval Supplement (PAS) to the FDA seeking to expand the label of KHINDIVI (hydrocortisone) oral solution to include younger pediatric patients (currently approved for ages 5+). The new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, and potential approval is targeted for the first half of 2027 — a meaningful expansion opportunity into the largest segment of the pediatric adrenal insufficiency market.
Key Facts
- Eton submitted a PAS to the FDA to expand the indication of KHINDIVI (hydrocortisone) oral solution to younger pediatric patients
- New formulation successfully demonstrated bioequivalence to ALKINDI SPRINKLE (hydrocortisone) oral granules
- Potential FDA approval of the expanded label targeted for the first half of 2027
- KHINDIVI is currently approved for pediatric patients ages 5 years and older with adrenocortical insufficiency
- Eton estimates approximately 10,000 pediatric adrenal insufficiency patients in the U.S.
Financial Impact
Label expansion to younger children could significantly increase total addressable market for KHINDIVI, but no financial figures were provided in the filing
Risk Factors
- FDA may reject or delay the PAS, requiring additional data or safety reviews
- Current safety warnings for excipients (hyperosmolarity risk in children under 5) could complicate label expansion
- Competitive positioning vs. ALKINDI SPRINKLE and compounded formulations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-024746 |
| Exhibit: ex_992515.htm | 0001437749-26-024746 |
| Document: 0001437749-26-024746-index-headers.html | 0001437749-26-024746 |
| Document: 0001437749-26-024746-index.html | 0001437749-26-024746 |
| Document: 0001437749-26-024746.txt | 0001437749-26-024746 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $52.88 | awaiting T+60 | — | $51.16 (−3.25%) |
Oct 6, 2026 21d ago | 144 | $54.88 | awaiting T+60 | — | $51.16 (−6.78%) |
Sep 28, 2026 29d ago | 8-K | $59.18 | awaiting T+60 | — | $51.16 (−13.55%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $51.16 (−15.34%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $51.16 (−15.35%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $51.16 (+18.86%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $51.16 (+16.79%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 4, 2026 12w ago | 8-K | $45.83 | awaiting T+60 | — | $51.16 (+11.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers